Safety Outcomes
No laboratory measurements showed abnormal findings that could be
attributable to treatment with nebulised UFH and in particular, there
were no significant differences in APTT between the two treatment
groups.
There were no cases recorded of pulmonary bleeding, heparin induced
thrombocytopaenia, or anaphylaxis during or immediately after
administration of nebulised UFH, or any other adverse events.